AmoyDx® NRAS Mutation Detection Kit | 8.01.25001X024H/8.01.25001W008A

AmoyDx® NRAS Mutation Detection Kit | 8.01.25001X024H/8.01.25001W008A | Gentaur UK, US & Europe Distribution  

The RAS proto-oncogenes (HRAS, KRAS and NRAS) encode a family of GDP/GTP-regulated switches that convey extracellular signals to regulate the growth and survival properties of cells. GTP-bound RAS transmits its signal through downstream EGFR signaling pathways, for example the RAF—MEK—ERK and PI3K—AKT cascades. RAS family members are frequently found in their mutated, oncogenic forms in human tumors. In total, activating mutations in the NRAS genes occur in 13〜25% of cutaneous melanomas, 1~6% of colorectal cancer and 1% of lung cancer, mainly in exons 2, 3 or 4. The mutation status of NRAS gene is relevant to drug resistance of colorectal cancers treated with anti-EGFZ? monoclonal antibodies. As a result, NRAS mutations detection supplies evidence for targeted clinical therapy of tumor patients, decreases cost and time of treatment.

Intended Use

The AmoyDx® NRAS Mutation Detection Kit is a real-time PCR assay for qualitative detection of 16 somatic mutations in codons 12, 13, 59, 61, 117 and 146 of NRAS gene in human genomic DNA extracted from formalin-fixed paraffin-embedded (FFPE) tumor tissue. The kit is intended to assess NRAS mutation status in colorectal cancer patients.

The kit is for in vitro diagnostic use, and intended to be used by trained professionals in a laboratory environment.

Testing Procedure